Pure red cell aplasia associated with myelodysplastic syndromes [4]

Leukemia

Volumn 14, Issue 9, 2000, Pages 1709-1710

  Park, S ^a   Merlat, A ^a   Guesnu, M ^a   Picard, F ^a   Viguie F ^b   Vassilieff, D ^a   Dreyfus, F ^a  

^a Hôpital Cochin APHP ^*  (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; IMMUNOGLOBULIN G;

ADULT; AGED; BONE MARROW BIOPSY; CHROMOSOME 5Q; CLINICAL ARTICLE; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; GENE DELETION; GENETIC LINKAGE; HUMAN; KARYOTYPE; LETTER; MALE; MALIGNANT TRANSFORMATION; MORTALITY; MYELODYSPLASTIC SYNDROME; PARVOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PURE RED CELL ANEMIA; SEPSIS; VIRUS INFECTION;

EID: 0033832864     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401833     Document Type: Letter

References (8)

1. Red cell aplasia in myelodysplastic syndrome
2. Myelodysplastic syndrome with erythroid hypoplasia/aplasia: A case report and review of the literature
3. The 5q-syndrome: An underdiagnosed form of macrocytic anaemia
4. Pure red cell aplasia: Association with large granular lymphocyte leukemia and the prognosis value of cytogenetics abnormalities
5. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
6. Poor response rate to a continuous schedule of amifostine therapy for 'low/intermediate risk' myelodysplastic patients
7. Pure red cell aplasia: Lymphocyte inhibition of erythropoiesis
8. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome